1,969 Eli Lilly and Company $LLY Shares Bought by Summit Global Investments

Summit Global Investments raised its position in Eli Lilly and Company (NYSE:LLY) by 18.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,376 shares of the company’s stock after acquiring an additional 1,969 shares during the quarter. Eli Lilly and Company makes up 0.7% of Summit Global Investments’ portfolio, making the stock its 16th biggest holding. Summit Global Investments’ holdings in Eli Lilly and Company were worth $14,319,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Invera Wealth Advisors LLC increased its stake in shares of Eli Lilly and Company by 16.1% in the 3rd quarter. Invera Wealth Advisors LLC now owns 1,812 shares of the company’s stock worth $2,097,000 after purchasing an additional 251 shares in the last quarter. Aprio Wealth Management LLC raised its holdings in Eli Lilly and Company by 3.9% in the 3rd quarter. Aprio Wealth Management LLC now owns 7,326 shares of the company’s stock worth $8,476,000 after purchasing an additional 274 shares during the period. Modera Wealth Management LLC lifted its position in Eli Lilly and Company by 6.5% during the third quarter. Modera Wealth Management LLC now owns 48,573 shares of the company’s stock valued at $56,202,000 after purchasing an additional 2,976 shares in the last quarter. Greenup Street Wealth Management LLC lifted its position in Eli Lilly and Company by 37.0% during the third quarter. Greenup Street Wealth Management LLC now owns 4,131 shares of the company’s stock valued at $4,780,000 after purchasing an additional 1,115 shares in the last quarter. Finally, CFC Planning Co LLC grew its holdings in Eli Lilly and Company by 53.5% during the third quarter. CFC Planning Co LLC now owns 2,547 shares of the company’s stock valued at $2,949,000 after purchasing an additional 888 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,415.64 on Monday. The stock’s 50-day simple moving average is $1,197.72 and its 200-day simple moving average is $1,092.57. Eli Lilly and Company has a 52 week low of $834.19 and a 52 week high of $1,449.68. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter last year, the business posted $7.02 earnings per share. The firm’s revenue was up 38.6% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. HSBC upped their price target on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective on the stock in a research report on Tuesday, September 15th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Leerink Partners boosted their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research note on Wednesday, October 21st. Finally, Guggenheim increased their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,398.43.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.